AnaptysBio Inc. (ANAB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 8.4% FCF Margin ($19.6M FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
Even with a 61/100 (C-) score, ANAB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($51.76) or 200D SMA ($50.40) invalidates the momentum regime and cuts Target Base ($49.30) toward Bear Floor ($38.45).
AnaptysBio Inc. (ANAB) dropped -3.68% to $48.64, trading at 55% of its 52-week range ($20.18 – $72.36). Solid steady margins (85% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its
GSK’s surprise early FDA approval for Jemperli in certain MSI-H and dMMR locally advanced rectal cancers has pushed AnaptysBio (ANAB) into focus, given its role in discovering and out licensing the antibody. The fresh Je
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military.
Explore why the fund outperformed the Russell 2500 despite a 4.75% decline, with key winners, laggards, and performance insights.
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after median follow up of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +157.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANAB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANAB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, AnaptysBio Inc. (ANAB) ranks #185 by composite RQD confidence (61/100, grade C-) and #311 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, ANAB leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANAB
ACTIVE
AnaptysBio Inc. | C- | 61/100 | — | — | 85.0% | -3.68% | $1.44B | Benchmark Subject |
| PCRX Pacira BioSciences Inc. | D+ | 54/100 | — | 79.4% | 1.7% | 0.00% | $1.45B | /pcrx-vs-anab → |
| GHRS GH Research PLC | D+ | 58/100 | — | — | — | +3.82% | $1.47B | /ghrs-vs-anab → |
| TYRA Tyra Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -1.24% | $1.48B | /tyra-vs-anab → |
| AAPG Ascentage Pharma Group International American Depository Shares | D+ | 57/100 | — | — | — | -0.70% | $1.39B | /aapg-vs-anab → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), AnaptysBio Inc. (ANAB) reported GAAP revenue of $234.6M (+157.0% vs. FY2024 revenue of $91.3M , and +1267.4% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of $19.7M, and free cash flow of $19.6M (+114.5% YoY). On the balance sheet, ANAB closed FY2025 with $364.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $234.6M | -$13.2M | $19.7M | $19.6M | $364.4M | — |
| FY2024 (FY) | 2024-12-31 | $91.3M | -$145.2M | -$135.3M | -$135.7M | $483.8M | — |
| FY2023 (FY) | 2023-12-31 | $17.2M | -$163.6M | -$120.8M | -$120.8M | — | — |
As of 2026-11-01, AnaptysBio Inc. (NASDAQ: ANAB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $48.64 (-3.68% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ANAB ranks #185 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANAB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, PCRX (Pacira BioSciences Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B) and GHRS (GH Research PLC) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B). Among the 5-stock peer group, ANAB leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
Per ANAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001370053), AnaptysBio Inc. generated $234.6M in revenue (+157.0% YoY), -$13.2M in net income, and $19.6M in free cash flow against $364.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANAB last traded at $48.64 (-3.68% on volume of 414,400 shares), positioning the stock -6.03% below its 50-day simple moving average ($51.76) and -3.49% below its 200-day simple moving average ($50.40). Across its 52-week range of $20.18 to $72.36, ANAB sits at the 54.5% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($43.87 to $53.41).
Why ANAB Stock dropped -3.68% Today — RQD Quant Desk Flash. Solid steady margins (85% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.